Implications from the air force/texas coronary atherosclerosis prevention study for the adult treatment panel III guidelines

American Journal of Cardiology

Volumn 96, Issue 12, 2005, Pages 1674-1680

  Clearfield, Michael ^a   Downs, John R ^b   Lee, Michael ^c   Langendorfer, Alex ^c   McConathy, Walter ^a   Gotto Jr , Antonio M ^d  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN;

ACUTE HEART INFARCTION; AIR FORCE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONFIDENCE INTERVAL; CORONARY ARTERY ATHEROSCLEROSIS; EDUCATION PROGRAM; EVALUATION; HEART PROTECTION; HUMAN; METABOLIC SYNDROME X; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLICATION; REVIEW; RISK ASSESSMENT;

EID: 29044441589     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2005.07.079     Document Type: Article

References (18)

1. J.R. Downs, M. Clearfield, S. Weis, E. Whitney, D. Shapiro, P. Beere, A. Langendorfer, E.A. Stein, W. Kruyer, A.M. Gotto Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels JAMA 279 1998 1615 1622
2. J.R. Downs, P.A. Beere, E. Whitney, M. Clearfield, S. Weis, J. Rochen, E.A. Stein, D. Shapiro, A. Langendorfer, A.M. Gotto Design and rationale of the AFCAPS/TexCAPS study Am J Cardiol 80 1997 287 293
3. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults Executive summary of the third report of the National Cholesterol Education Program (NCEP) (Adult Treatment Panel III) JAMA 285 2001 2486 2497
4. S.M. Grundy, J.I. Cleeman, C.N. Bairey, B. Brewer, L.T. Clark, D.B. Hunninghake, R.C. Pasternak, S.C. Smith, N.J. Stone Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2004 227 229
5. Expert Committee in the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on diagnoses of diabetes mellitus Diabetes Care 26 2003 3160 3176
6. S.M. Grundy, H.B. Brewer, J.I. Cleeman, S.C. Smith, C. Lenfant Conference Participants Definition of metabolic syndrome report of the National Heart, Lung and Blood Institute/American Heart Association conference on scientific issues related to definition Circulation 109 2004 433 438
7. G. Assmann, P. Cullen, H. Schulte Simple scoring scheme for calculating risk of acute coronary events based on the 10 year follow-up of the Prospective Cardiovascular Munster (PROCAM) study Circulation 105 2002 310 315
8. K.O. Akosh, A. Schaper, Cogbill, P. Schoenfeld Preventing myocardial infarction in the young adult in the first place How do the National Cholesterol Education Panel III guidelines perform? Am J Cardiol 41 2003 1475 1479
9. C.M. Alexander, P.B. Landsman, S.M. Teutsch, S.M. Haffner NCEP defined metabolic syndrome, diabetes, and prevalence of CHD among NHANES III participants age 50 years and older Diabetes 52 2003 1210 1214
10. P.S. Sever, B. Dahlof, N.R. Poulter, H. Wedel, G. Beervers, M. Caulfield, R. Collins, S.E. Kjeldsen, A. Kristinsson, G.T. McInnes Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower than average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial Lancet 361 2003 1149 1158
11. Y. Cui, R.S. Blumenthal, J.A. Flaws, M.K. Whiteman, P. Langenberg, P.S. Bachorik, T.L. Bush Non-HDL-C level as predictor of cardiovascular disease mortality Arch Intern Med 161 2001 1413 1420
12. S. Grundy Non-HDL-C as potential risk predictor and therapy target Arch Intern Med 161 2001 1379 1380
13. H.F. Frost, R.J. Havel Rationale for use of non-HDL-C rather than LDL-C as tool for lipoprotein cholesterol screening and assessment of risk and therapy Am J Cardiol 81 suppl 1998 26B 31B
14. A.M. Gotto, E. Whitney, E. Stein, D. Shapiro, M. Clearfield, S. Weis, J. Jou, A. Langendorfer, P. Beere, D. Watson, J.R. Downs, J.S. deCani Relation between baseline and on-treatment lipid parameters and first acute major coronary event in AFCAPS/TexCAPS Circulation 101 2000 477 484
15. S. Yusef, S. Hawken, S. Ounpuu, T. Dans, A. Avezum, F. Lanas, M. McQueen, A. Budaj, P. Pais, J. Varigos, L. Lisheng INTERHEART Study Investigators Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study) case control study Lancet 364 2004 937 952
16. D. von Muhlen, R.D. Langer, E. Barrett-Conner Sex and time differences in the associations of non-HDL lipoprotein factors in the prediction of cardiovascular death Am J Cardiol 91 2003 1311 1315
17. A.D. Sniderman, A.C. St-Pierre, B. Cantin, G.R. Dagenais, J.P. Despres, B. Lamarche Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk Am J Cardiol 91 2003 1173 1177
18. N. Sattar, K. Williams, A.D. Sniderman, R. D'Agostino, S.M. Haffner Comparison of the associations of apolipoprotein B and non-HDL lipoprotein cholesterol with other cardiovascular risk factors in patients with the metabolic syndrome in the Insulin Resistance Atherosclerosis Study Circulation 110 2004 2687 2693